NtRON Bio announced today, following its recent U.S. patent application related to colorectal cancer using the IMPA™ phage engineering technology, it has now completed the filing of two patents for a ...

As the first wave of gene therapies for transfusion-dependent β-thalassemia (TDT) continues to roll out in the U.S., a new conversation is emerging within the hematology community: whether the future ...

On a special episode (first released on June 20, 2024) of The Excerpt podcast: With the advent of CRISPR as a gene editing technology, there are new opportunities to develop breakthrough ...

Bio-Gene Technology Ltd. ( ($AU:BGT) ) has issued an announcement. Bio-Gene Technology Ltd. has released its Corporate Governance Statement, ...

The latest announcement is out from Bio-Gene Technology Ltd. ( ($AU:BGT) ). Bio-Gene Technology Limited released its 2025 Annual Report, ...

The inaugural Genetic Agency Technology Conference (GATC) on November 11th, 2025 will convene technical thought leaders, gene therapy developers, patients, their families, and patient advocates ...

This technology can relate the distinct treatment responses of individual cancer cells to their molecular profiles prior to treatment, and compare the gene expression characteristics of cancer ...

There's a fresh push to edit the genes of human embryos to prevent diseases and enhance characteristics that parents value.

The ClvRsystem uses CRISPR/Cas9 gene editing technology to ensure that if a gamete does not contain the desired gene, it will not survive. In this way, any future offspring will come from gametes ...

On the heels of the U.K.'s authorizing the world’s first gene-edited treatment for sickle cell disease on Nov. 16, the U.S. Food and Drug Administration (FDA) approved the same treatment on Dec. 8.